These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1821614)

  • 1. Immunological markers of the subsets of systemic scleroderma and its overlap.
    Jabłońska S; Błaszczyk M; Jarzabek-Chorzelska M; Chorzelski T; Kołacińska-Strasz Z
    Arch Immunol Ther Exp (Warsz); 1991; 39(4):381-90. PubMed ID: 1821614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Scl-70 antibody and its clinical significance].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1989; 175(3):133-47. PubMed ID: 2653887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scl 70 antibody--a specific marker of systemic sclerosis.
    Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
    Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nuclear antibodies as serologic markers in progressive systemic scleroderma].
    Lakomek HJ; Guldner HH; Bautz FA; Goerz G; Kind P; Mensing H; Krüskemper HL
    Hautarzt; 1987 Feb; 38(2):63-9. PubMed ID: 3106261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antinuclear, anticentromere and anti-ScL-70 antibodies in rheumatic diseases].
    Ivanova SM; Melkumova KL; Il'in KV; Riazantseva TA; Piven' VA; Speranskiĭ AI
    Lab Delo; 1990; (6):50-3. PubMed ID: 1699041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies.
    Cassani F; Tosti A; Bianchi FB; Fusconi M; Selleri L; Baffoni L; Veronesi S; Volta U; Lenzi M; Pisi E
    Clin Exp Rheumatol; 1987; 5(1):23-8. PubMed ID: 3109797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The PM-Scl (polymyositis-scleroderma) autoantibody and its nucleolar fluorescence pattern].
    Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski TP; Jablonska S
    Dermatol Monatsschr; 1989; 175(8):479-83. PubMed ID: 2676628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.
    Vázquez-Abad D; Grodzicky T; Senécal JL
    Clin Immunol; 1999 Feb; 90(2):182-9. PubMed ID: 10080829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.
    Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski T; Jabłońska S; Maul GG
    Arch Dermatol Res; 1990; 282(2):76-83. PubMed ID: 2162156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-Scl-70 antibodies in systemic scleroderma].
    Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
    Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis.
    Giordano M; Valentini G; Migliaresi S; Picillo U; Vatti M
    J Rheumatol; 1986 Oct; 13(5):911-6. PubMed ID: 3546686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA.
    Mahler M; You D; Baron M; Taillefer SS; Hudson M; ; Fritzler MJ
    Clin Chim Acta; 2011 Oct; 412(21-22):1937-43. PubMed ID: 21756890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
    Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
    Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases)].
    Admou B; Arji N; Seghrouchni F; Missoum H; El Fenniri L; Amghar S; El Aouad R
    Ann Biol Clin (Paris); 2007; 65(3):291-7. PubMed ID: 17502303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Centromere antibodies and antibodies against Scl 70 nucleoprotein in progressive systemic scleroderma. Diagnostic and prognostic significance].
    Meurer M; Scharf A; Luderschmidt C; Braun-Falco O
    Dtsch Med Wochenschr; 1985 Jan; 110(1):8-14. PubMed ID: 3880700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives.
    Harvey G; Black C; Maddison P; McHugh N
    J Rheumatol; 1997 Mar; 24(3):477-84. PubMed ID: 9058652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pulmonary manifestation of progressive systemic scleroderma: prognostic value of centromere antibodies and antibodies to Scl-70 nucleoprotein].
    Behr J; König G; Meurer M; Krieg T
    Pneumologie; 1990 Jun; 44(6):822-5. PubMed ID: 2381889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
    Mahler M; Raijmakers R; Dähnrich C; Blüthner M; Fritzler MJ
    Arthritis Res Ther; 2005; 7(3):R704-13. PubMed ID: 15899056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are ACA and Scl 70 antibodies mutually exclusive?
    Jarzabek-Chorzelska M; Błaszczyk M; Kołacińska-Strasz Z; Jabłonska S; Chorzelski T; Maul GG
    Br J Dermatol; 1990 Feb; 122(2):201-8. PubMed ID: 2107867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.